Company / PP&E (Net)
Aurinia Pharmaceuticals Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.1M
FY2025
5-year range
$2.1M / $4.4M
FY2021-FY2025
Trend
-22.7%
vs FY2024
Sector context
#132 of 193
Health Care
What the data says
At $2M, Aurinia Pharmaceuticals Inc.'s pp&e (net) ranks #132 of 193 in the Health Care sector. PP&E (Net) has declined for 5 consecutive years, from $5M in FY2020 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -15.1%.
Declined from $3M to $2M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -16.7%
- 5-Year CAGR
- -15.1%
- 10-Year CAGR
- -
Sector benchmark
#132 of 193 in Health CareTop 68% of 193This company $2.1M Sector average $777.6M
▼
-99.7% below sector average
Key checks
Key Insights
- Aurinia Pharmaceuticals Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -15.1%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 22.7% year-over-year.
- Ranks #132 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1M | -22.7% |
| FY2024 | $2.7M | -18.6% |
| FY2023 | $3.4M | -8.1% |
| FY2022 | $3.6M | -17.4% |
| FY2021 | $4.4M | -7.7% |
| FY2020 | $4.8M | +5046.2% |
| FY2019 | $93.0K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026